Company news
Alterity Therapeutics Ltd. (ASX:ATH) news
Alterity Therapeutics Ltd. news releases on 6ix. Latest, Oct 13, 2022: ATH434 Clinical Trial launched in Australia
Press releases — page 3
ATH434 Clinical Trial launched in Australia
October 13, 2022
US FDA Approval for IND Application for ATH434 for MSA
September 19, 2022
Appendix 4E & Annual Report 2022
August 31, 2022
ATH434 Phase 2 clinical launched in Europe
August 25, 2022
First Patient dosed in ATH434 Phase 2 Clinical Trial
July 6, 2022
Alterity receives a $4.1 million R&D Tax Refund
June 30, 2022
Regulatory Approval to Proceed with Phase 2 Trial in Italy
June 22, 2022
Alterity Launches ATH434 Phase 2 Clinical Trial
June 2, 2022
UK Regulatory Authorisation to Proceed with Phase 2 Trial
April 27, 2022
New publication shows ATH434 rescues neurons in MSA model
January 28, 2022
Response to ASX Query
January 12, 2022
New US Patent for Compounds to Treat Neurodegeneration
January 5, 2022
First Regulatory Authorization to Proceed with Phase 2 Trial
December 13, 2021
ATH Annual General Meeting Presentation
November 11, 2021
Chairmans Address 2021 Annual General Meeting
November 11, 2021
New Data Advance ATH434 as Neurodegeneration treatment
November 4, 2021
Expanded ATH434 Phase 2 Clinical Development Program
October 18, 2021
Form 20-F
September 3, 2021
Appendix 4E & Annual Report 2021
August 31, 2021
New US Patent Expands Neurodegeneration Treatment Portfolio
August 4, 2021
New Publication Demonstrates ATH434 is Neuroprotective
July 15, 2021
New US patent targeting major neurodegenerative diseases
July 1, 2021
EU Regulatory Guidance for ATH434 Phase 2 Clinical Trial
June 23, 2021
ATH434 protects brain cells and improves motor function
April 21, 2021
Alterity to present at Global Life Science Conference
March 10, 2021
Michael J Fox grant for Parkinsons research on ATH434
February 8, 2021
Alterity participates in JP Morgan healthcare conference
January 11, 2021
Dr David Stamler Appointed CEO
January 6, 2021
Form F-3
December 23, 2020
New commercial opportunity for PBT2
December 21, 2020
Alterity presents at Finance News Network
December 1, 2020
Prospectus filed pursuant to SEC Rule 424(b)(3)
November 24, 2020
Chairmans Address 2020 Annual General Meeting
November 17, 2020
US patent for next generation neurodegenerative diseases
November 15, 2020
MSA patients enrolled in bioMUSE Study
October 26, 2020
Alterity completes Placement Tranche 1 raising $10M
October 23, 2020
Alterity raises $35M in placement to institutional investors
October 15, 2020
Company update on Annual Report 2020
September 9, 2020
Preliminary Final Report
August 30, 2020
New data independently confirms safety profile of ATH434
August 4, 2020
Pause in Trading
July 1, 2020
Meeting with US FDA provides development path for ATH434
June 30, 2020
Presentation on ATH434 to American Academy of Neurology
May 20, 2020
Appendix 4C and Quarterly Update
April 30, 2020
NASDAQ Temporary Relief
April 22, 2020
NASDAQ Non-Compliance Notice Received
February 7, 2020
Appendix 4C - quarterly
January 31, 2020
Alterity receives a $4.8 million R&D Tax Incentive Refund
January 14, 2020
European Orphan Designation granted for PBT434 for MSA
January 13, 2020
AGM Presentation 2019
November 25, 2019